On February 02, 2023, LivaNova PLC, a medical innovation and technology company, has launched an implantable pulse generator (IPG) SenTiva DUO™, useful for VNS Therapy™ of drug-resistant epilepsy.
With a dual-pinned header, it offers similar therapeutic benefits as SenTiva, the company's earlier product, which stimulates a response to the rapid heart rate, which can be a result of seizures, the low heart rate, and similar situations with day and night programming and scheduled programming. It recently received 510(k) clearance from the United States Food and Drug Administration and is now available for purchase in the United States.
Professor and Chief Pediatric Neurology at Le Bonheur Children's Hospital in Memphis, Tennessee, Dr. James Wheless, said, "This new offering enables those VNS Therapy patients with legacy dual-pin systems to have the option to replace their device with SenTiva DUO, delivering the most advanced VNS Therapy treatment without the need for lead revision." He added, "Having access to SenTiva DUO offers patients therapy that can be customized and delivered automatically, providing optimal seizure control and enabling maximum adherence to treatment."
(Source – Business Wire)
Chief Executive Officer of LivaNova, Damien McDonald, said, "We're proud to offer SenTiva DUO to serve patients who were early adopters of VNS Therapy many years ago. Over time, all VNS Therapy patients must replace their generators as batteries become depleted. Now, our 'pioneer patients' will be able to take advantage of the latest technology with SenTiva DUO and experience the full benefits of VNS Therapy, without the need to replace their dual-pin lead."
(Source – Business Wire)
About LivaNova
LivaNova PLC is transforming the lives of patients all over the world with its innovation and technological advancements in the medical field, providing clinical and financial support by offering various products and a global reach. Its advanced technologies and revolutionary treatment solutions have benefited healthcare professionals, healthcare systems, and patients worldwide. Headquartered in London (UK), it has about 3,000 employees worldwide and a presence in over 100 countries. Its products work for therapeutic areas like advanced circulatory support, cardiopulmonary, obstructive sleep apnea, heart failure, difficult-to-treat depression (DTD), and drug-resistant epilepsy.